Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
Thierry Conroy(Inserm), Antoine Adenis(Inserm), Laurent Bedenne(CHU Dijon Bourgogne), Valérie Boige(Inserm), G. Créhange(Centre Georges François Leclerc), Isabelle Martel‐Lafay(Centre Léon Bérard), C. Llacer-Moscardo(Inserm), Pierre-Luc Etienne, Pierre Michel(Aix-Marseille Université), Olivier Bouché(CHU Dijon Bourgogne), Béata Juzyna(Université Paris Cité), Jean‐Luc Raoul(Institut de Cancérologie de l'Ouest), Marie‐Pierre Galais(Centre François Baclesse), E. François(Université Paris Cité), S. Gourgou-Bourgade(CEA Valduc), Jean‐Yves Douillard(Integrated Oncology (United States)), Méher Ben Abdelghani(Université Paris Cité)
Cited by 446
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k